跳至主要内容
临床试验/EUCTR2013-002037-38-NL
EUCTR2013-002037-38-NL进行中(未招募)不适用

The effect of correction of metabolic acidosis in chronics kidney disease on intrarenal RAS activity. - BIC study

未提供0 个研究点开始时间: 2013年7月30日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - male or female adult (>18 years)
  • - chronic kidney disease stage 4, i.e. eGFR (MDRD) 15-30 ml/min
  • - plasma bicarbonate concentration of <24 and >15 meq/L, the latter
  • because in that case it seems highly recommended to start
  • sodiumbicarbonate suppletion and not to postpone this
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 22
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 23

排除标准

  • - plasma bicarbonate level >24 meq/L or <15 meq/L
  • - sodiumbicarbonate use in the 1 month preceeding the study
  • - a kidney transplant in situ
  • - heart failure
  • - liver cirrhosis
  • - resistant hypertension (blood pressure >140/90 mmHg despite the use of 3 or more different antihypertensives
  • - a history of inadherence to medication
  • - use of calcineurin inhibitors (these immunosuppressive drugs are
  • known to induce metabolic acidosis and influence electrolytes and acidbase

研究者

发起方
未提供

相似试验